Fulgent Genetics Inc (Fulgent) is a technology-based company engaged in laboratory services and therapeutic development. The company provides technical laboratory and testing services, along with professional interpretation of laboratory results by licensed physicians. It focuses on developing product candidates for cancer treatment using a nanoencapsulation and targeted therapy platform. Fulgent serves industries related to healthcare, biotechnology, and pharmaceuticals. The company also provides testing services and licensing to pharmaceutical and biotech companies, contract research organizations, and sponsored testing programs under its BioPharma services. Fulgent's proprietary technology platform supports its laboratory services with gene probes, AI learning software, and laboratory information management systems.The company is also advancing antibody drug conjugates using its patented linker and payload platform technology. Fulgent's customers include insurance companies, institutional clients such as hospitals and medical institutions, and patients who pay directly for services. Fulgent focuses on a nano-drug delivery platform for cancer treatment, with product candidates like FID-007 and FID-022 in clinical trials.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Fulgent's R&D arm focuses on bioinformatics, genetics, software engineering, AI R&D engineering, and laboratory management to conduct research and development activities related to its laboratory services business. The company focuses on developing and curating an expansive library of genetic information and expanding its testing services technology platform. Fulgent Genetics Inc launched its Ultra Rapid Whole Genome Sequencing service in 2025. The company is also involved in pre-clinical studies and clinical trials, including the investigation of FID-007 and FID-022 for cancer treatment. Additionally, Fulgent Genetics Inc is advancing the development of antibody drug conjugates (ADCs) using its novel patented linker and payload platform technology. The R&D unit of Fulgent is responsible for conducting research and development activities related to the company's laboratory services business. This includes efforts to develop and curate the company's library of genetic information and expand its testing services technology platform. The unit also manages pre-clinical studies and clinical trials for product candidates like FID-007 and FID-022. As of December 31, 2025, the company owns or exclusively in-licenses over 20 issued or allowed patents and over 10 active patent applications. The company has pipeline products including FID-007 and FID-022, which are currently in clinical studies. Fulgent has a major technology alliance through an exclusive license agreement with ANP Technologies, Inc. In FY2025, the company spent US$53.9 million on its R&D activities, which as a percentage of revenue stood at 16.7%.